AB
PRLD icon

Amalgamated Bank’s Prelude Therapeutics PRLD Stock Holding History

Amalgamated Bank’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-334
Closed – – 3108
2025
Q1 		$0 Hold
334
– – ﹤0.01% 2960
2024
Q4 		$0 Hold
334
– – ﹤0.01% 2980
2024
Q3 		$1K Hold
334
– – ﹤0.01% 2969
2024
Q2 		$1K Hold
334
– – ﹤0.01% 2986
2024
Q1 		$2K Sell
334
-530
-61% -$2.06K ﹤0.01% 2901
2023
Q4 		$4K Sell
864
-100
-10% -$304 ﹤0.01% 2959
2023
Q3 		$3K Hold
964
– – ﹤0.01% 2995
2023
Q2 		$4K Buy
+964
New +$5.76K ﹤0.01% 3007
2022
Q2 		– Sell
-1,764
Closed -$12K – 3163
2022
Q1 		$12K Buy
+1,764
New +$16.1K ﹤0.01% 2926

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Amalgamated Bank's PRLD Position: Q2 2025 in Review

Amalgamated Bank sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 334 shares.

Amalgamated Bank first reported a position in PRLD in Q1 2022 and held it in 9 quarters. The position peaked at $12K in Q1 2022. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Amalgamated Bank reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 334 Prelude Therapeutics shares in Q2 2025.
  • Amalgamated Bank first reported a position in Prelude Therapeutics in Q1 2022 and held it in 9 quarters.
  • Amalgamated Bank's Prelude Therapeutics position peaked at $12K in Q1 2022.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.